<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740791</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-281-0102</org_study_id>
    <nct_id>NCT01740791</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection</brief_title>
  <official_title>Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety, tolerability, and antiviral&#xD;
      activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes&#xD;
      1-6.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2012</start_date>
  <completion_date type="Actual">January 24, 2014</completion_date>
  <primary_completion_date type="Actual">March 15, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment Emergent Adverse Events</measure>
    <time_frame>First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing)</time_frame>
    <description>Treatment-emergent adverse events were defined as any new or worsening adverse event that began on or after the date of the first dose of study drug until the Day 17 study visit date + 2 (Day 19 if Day 17 visit missing).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities</measure>
    <time_frame>First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing)</time_frame>
    <description>A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline at any postbaseline visit up to the Day 17 visit date + 2 days (or Day 19 if Day 17 visit was missing). The criteria used to grade laboratory results were as follows: Grade 1 (mild), Grade 2 (moderate), or Grade 3 (severe). Graded laboratory abnormalities were defined using the grading scheme defined in protocol (Gilead Sciences, Inc. Grading Scale for Severity of Adverse Events and Laboratory Abnormalities) for analysis purpose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline</measure>
    <time_frame>Baseline; Days 4, 5, 6, 7, 8, 10, and 17</time_frame>
    <description>Participants who were genotyped incorrectly but received appropriate treatment for that genotype were included in that treatment group for the efficacy analysis. Data were summarized by treatment and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute HCV RNA Level</measure>
    <time_frame>Baseline; Days 4, 5, 6, 7, 8, 10, and 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Reductions From Baseline in HCV RNA</measure>
    <time_frame>Baseline; Days 4, 5, 6, 7, 8, 10, and 17</time_frame>
    <description>Categorical declines from baseline were summarized by the number of participants with a &lt; 1, ≥ 1 to &lt; 2, ≥ 2 to &lt; 3, or ≥ 3 log10 IU/mL decrease in HCV RNA from baseline by treatment (velpatasvir dose/HCV genotype) and placebo at each collection time point through Day 17.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have HCV RNA &lt; Lower Limit of Quantitation (LLOQ) Detected</measure>
    <time_frame>Days 4, 5, 6, 7, and 8</time_frame>
    <description>The lower limit of quantitation (LLOQ) detection for HCV RNA levels was 25 IU/mL. HCV detected means calculated HCV RNA level is below LLOQ of the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HCV RNA Levels by Treatment and IL28B Genotype</measure>
    <time_frame>Days 4, 5, 6, 7, 8, 10, and 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Velpatasvir: AUCtau</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 3</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Velpatasvir: Cmax</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1 for single dose and Day 3 for multiple dose.</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Velpatasvir: CL/F</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1 for single dose and Day 3 for multiple dose</time_frame>
    <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Velpatasvir: Ctau</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 3</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints</measure>
    <time_frame>First dose date up to Day 17</time_frame>
    <description>The full-length NS5A coding region was analyzed pretreatment (baseline) by deep sequencing using MiSeq for all 70 participants who received velpatasvir and for 8 of 17 participants who received placebo prior to and up to 2 weeks (Day 17) after dosing with velpatasvir. Participants were categorized by velpatasvir dose/HCV genotype and presence or absence of NS5A RAVs.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Chronic Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Velpatasvir 5 mg (GT 1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype (GT) 1a HCV infection will receive velpatasvir 5 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 25 mg (GT 1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 1a HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 50 mg (GT 1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 1a HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 100 mg (GT 1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 1a HCV infection will receive velpatasvir 100 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 150 mg (GT 1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 1a HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 150 mg (GT 1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 1b HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 150 mg (GT 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 2 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 25 mg (GT 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 3 HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 50 mg (GT 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 3 HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 150 mg (GT 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 3 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir 150 mg (GT 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 4 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velpatasvir up to 400 mg (GT 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT 2 HCV infection will receive velpatasvir up to 400 mg or placebo once daily for 3 days under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velpatasvir</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Velpatasvir 100 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 1b)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 2)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 3)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 4)</arm_group_label>
    <arm_group_label>Velpatasvir 25 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 25 mg (GT 3)</arm_group_label>
    <arm_group_label>Velpatasvir 5 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 50 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 50 mg (GT 3)</arm_group_label>
    <arm_group_label>Velpatasvir up to 400 mg (GT 2)</arm_group_label>
    <other_name>GS-5816</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Velpatasvir 100 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 1b)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 2)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 3)</arm_group_label>
    <arm_group_label>Velpatasvir 150 mg (GT 4)</arm_group_label>
    <arm_group_label>Velpatasvir 25 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 25 mg (GT 3)</arm_group_label>
    <arm_group_label>Velpatasvir 5 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 50 mg (GT 1a)</arm_group_label>
    <arm_group_label>Velpatasvir 50 mg (GT 3)</arm_group_label>
    <arm_group_label>Velpatasvir up to 400 mg (GT 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  HCV treatment-naive adult participants (18-65 years of age) with chronic HCV infection&#xD;
             and plasma HCV RNA ≥ 5 log10 IU/mL at screening&#xD;
&#xD;
          -  Agree to use protocol defined precautions against pregnancy&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease,&#xD;
             α1 antitrypsin deficiency, cholangitis)&#xD;
&#xD;
          -  Evidence of cirrhosis&#xD;
&#xD;
          -  Evidence of current drug abuse&#xD;
&#xD;
          -  Screening laboratory results outside the protocol specified requirements&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials, LLC</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Gastroenterology and Hepatology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research-Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles River Clinical Services Northwest, Inc.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion De Investigacion De Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hebner C, Gontcharova V, Chodavarapu RK, Rodriguez-Torres M, Lawitz E, Yang C, et al. Deep Sequencing of HCV NS5A From a 3-Day Study of GS-5816 Monotherapy Confirms the Potency of GS-5816 Against Pre-Existing Genotype 1-3 NS5A Resistance-Associated Variants [Abstract 470]. The Liver Meeting The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2013 November 1-5; Washington, D.C.</citation>
  </results_reference>
  <results_reference>
    <citation>Lawitz E, Glass SJ, Gruener D, Freilich B, Hill JM, Link JO, et al. GS-5816, a Once-Daily NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients with Genotype 1, 2, 3, or 4 HCV Infection in a 3-Day Monotherapy Study [Abstract 1082]. The Liver Meeting The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2013 November 1-5; Washington, D.C.</citation>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <results_first_submitted>October 27, 2020</results_first_submitted>
  <results_first_submitted_qc>December 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2020</results_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Genotype 2</keyword>
  <keyword>Genotype 3</keyword>
  <keyword>Genotype 4</keyword>
  <keyword>Genotype 5</keyword>
  <keyword>Genotype 6</keyword>
  <keyword>Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in United States. The first participant was screened on 06 November 2012. The last study visit occurred on 24 January 2014.</recruitment_details>
      <pre_assignment_details>163 participants were screened. Participants were not enrolled in 'Velpatasvir up to 400 mg genotype (GT) 2' group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="P2">
          <title>Velpatasvir 5 mg</title>
          <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="P3">
          <title>Velpatasvir 25 mg</title>
          <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="P4">
          <title>Velpatasvir 50 mg</title>
          <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="P5">
          <title>Velpatasvir 100 mg</title>
          <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="P6">
          <title>Velpatasvir 150 mg</title>
          <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but never treated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's discretion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug (velpatasvir or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="B2">
          <title>Velpatasvir 5 mg</title>
          <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="B3">
          <title>Velpatasvir 25 mg</title>
          <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="B4">
          <title>Velpatasvir 50 mg</title>
          <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="B5">
          <title>Velpatasvir 100 mg</title>
          <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="B6">
          <title>Velpatasvir 150 mg</title>
          <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="31"/>
            <count group_id="B7" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="11.46"/>
                    <measurement group_id="B2" value="44.8" spread="15.65"/>
                    <measurement group_id="B3" value="45.1" spread="11.56"/>
                    <measurement group_id="B4" value="46.9" spread="10.13"/>
                    <measurement group_id="B5" value="47.0" spread="8.40"/>
                    <measurement group_id="B6" value="49.2" spread="9.12"/>
                    <measurement group_id="B7" value="47.3" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA (log10 IU/mL)</title>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.52" spread="0.517"/>
                    <measurement group_id="B2" value="6.64" spread="0.312"/>
                    <measurement group_id="B3" value="6.32" spread="0.826"/>
                    <measurement group_id="B4" value="6.39" spread="0.558"/>
                    <measurement group_id="B5" value="6.46" spread="0.479"/>
                    <measurement group_id="B6" value="6.41" spread="0.603"/>
                    <measurement group_id="B7" value="6.43" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1a</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1b</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2b</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3a</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4a/4c/4d</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28B Genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>C/C</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>C/T</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T/T</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Treatment Emergent Adverse Events</title>
        <description>Treatment-emergent adverse events were defined as any new or worsening adverse event that began on or after the date of the first dose of study drug until the Day 17 study visit date + 2 (Day 19 if Day 17 visit missing).</description>
        <time_frame>First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing)</time_frame>
        <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug (velpatasvir or placebo). Data were summarized by velpatasvir or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 5 mg</title>
            <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 25 mg</title>
            <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 50 mg</title>
            <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 100 mg</title>
            <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Velpatasvir 150 mg</title>
            <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Treatment Emergent Adverse Events</title>
          <description>Treatment-emergent adverse events were defined as any new or worsening adverse event that began on or after the date of the first dose of study drug until the Day 17 study visit date + 2 (Day 19 if Day 17 visit missing).</description>
          <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug (velpatasvir or placebo). Data were summarized by velpatasvir or placebo.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="26.7"/>
                    <measurement group_id="O4" value="8.3"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities</title>
        <description>A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline at any postbaseline visit up to the Day 17 visit date + 2 days (or Day 19 if Day 17 visit was missing). The criteria used to grade laboratory results were as follows: Grade 1 (mild), Grade 2 (moderate), or Grade 3 (severe). Graded laboratory abnormalities were defined using the grading scheme defined in protocol (Gilead Sciences, Inc. Grading Scale for Severity of Adverse Events and Laboratory Abnormalities) for analysis purpose.</description>
        <time_frame>First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing)</time_frame>
        <population>Participants in the Safety Analysis Set were analyzed. Data were summarized by dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 5 mg</title>
            <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 25 mg</title>
            <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 50 mg</title>
            <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 100 mg</title>
            <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Velpatasvir 150 mg</title>
            <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities</title>
          <description>A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline at any postbaseline visit up to the Day 17 visit date + 2 days (or Day 19 if Day 17 visit was missing). The criteria used to grade laboratory results were as follows: Grade 1 (mild), Grade 2 (moderate), or Grade 3 (severe). Graded laboratory abnormalities were defined using the grading scheme defined in protocol (Gilead Sciences, Inc. Grading Scale for Severity of Adverse Events and Laboratory Abnormalities) for analysis purpose.</description>
          <population>Participants in the Safety Analysis Set were analyzed. Data were summarized by dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="58.3"/>
                    <measurement group_id="O5" value="62.5"/>
                    <measurement group_id="O6" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="8.3"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="13.3"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline</title>
        <description>Participants who were genotyped incorrectly but received appropriate treatment for that genotype were included in that treatment group for the efficacy analysis. Data were summarized by treatment and placebo.</description>
        <time_frame>Baseline; Days 4, 5, 6, 7, 8, 10, and 17</time_frame>
        <population>Participants in the Efficacy Analysis Set (all randomized participants with appropriate genotype who received at least one dose of the study drug (velpatasvir or placebo) and with at least one on-treatment HCV RNA assessment) with available data were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 5 mg (GT 1a)</title>
            <description>Participants with genotype (GT) 1a HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 25 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 50 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 100 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Velpatasvir 150 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Velpatasvir 150 mg (GT 1b)</title>
            <description>Participants with GT 1b HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Velpatasvir 150 mg (GT 2)</title>
            <description>Participants with GT 2 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Velpatasvir 25 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Velpatasvir 50 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Velpatasvir 150 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Velpatasvir 150 mg (GT 4)</title>
            <description>Participants with GT 4 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline</title>
          <description>Participants who were genotyped incorrectly but received appropriate treatment for that genotype were included in that treatment group for the efficacy analysis. Data were summarized by treatment and placebo.</description>
          <population>Participants in the Efficacy Analysis Set (all randomized participants with appropriate genotype who received at least one dose of the study drug (velpatasvir or placebo) and with at least one on-treatment HCV RNA assessment) with available data were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.3343"/>
                    <measurement group_id="O2" value="-3.104" spread="0.7348"/>
                    <measurement group_id="O3" value="-3.638" spread="0.4350"/>
                    <measurement group_id="O4" value="-3.338" spread="1.3088"/>
                    <measurement group_id="O5" value="-3.154" spread="1.0089"/>
                    <measurement group_id="O6" value="-3.648" spread="0.9270"/>
                    <measurement group_id="O7" value="-3.848" spread="0.4834"/>
                    <measurement group_id="O8" value="-4.044" spread="0.3671"/>
                    <measurement group_id="O9" value="-2.796" spread="1.4313"/>
                    <measurement group_id="O10" value="-2.382" spread="1.5028"/>
                    <measurement group_id="O11" value="-2.834" spread="0.7608"/>
                    <measurement group_id="O12" value="-3.269" spread="0.6080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.2346"/>
                    <measurement group_id="O2" value="-1.998" spread="0.8305"/>
                    <measurement group_id="O3" value="-3.538" spread="0.7566"/>
                    <measurement group_id="O4" value="-3.123" spread="1.5009"/>
                    <measurement group_id="O5" value="-3.060" spread="1.1098"/>
                    <measurement group_id="O6" value="-3.636" spread="1.0023"/>
                    <measurement group_id="O7" value="-3.955" spread="0.3519"/>
                    <measurement group_id="O8" value="-4.148" spread="0.5841"/>
                    <measurement group_id="O9" value="-2.617" spread="1.3034"/>
                    <measurement group_id="O10" value="-2.130" spread="1.4385"/>
                    <measurement group_id="O11" value="-2.259" spread="1.1488"/>
                    <measurement group_id="O12" value="-2.827" spread="0.5506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.2119"/>
                    <measurement group_id="O2" value="-1.244" spread="0.6135"/>
                    <measurement group_id="O3" value="-3.140" spread="0.9786"/>
                    <measurement group_id="O4" value="-2.704" spread="1.5100"/>
                    <measurement group_id="O5" value="-2.713" spread="1.1206"/>
                    <measurement group_id="O6" value="-3.221" spread="1.2323"/>
                    <measurement group_id="O7" value="-4.021" spread="0.3681"/>
                    <measurement group_id="O8" value="-4.109" spread="0.6408"/>
                    <measurement group_id="O9" value="-2.193" spread="1.1060"/>
                    <measurement group_id="O10" value="-1.737" spread="1.3854"/>
                    <measurement group_id="O11" value="-1.869" spread="1.3270"/>
                    <measurement group_id="O12" value="-2.243" spread="0.5919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.1923"/>
                    <measurement group_id="O2" value="-1.031" spread="0.6112"/>
                    <measurement group_id="O3" value="-2.424" spread="0.7292"/>
                    <measurement group_id="O4" value="-2.184" spread="1.5527"/>
                    <measurement group_id="O5" value="-2.273" spread="1.1753"/>
                    <measurement group_id="O6" value="-2.481" spread="1.3542"/>
                    <measurement group_id="O7" value="-4.205" spread="0.4393"/>
                    <measurement group_id="O8" value="-3.850" spread="0.9630"/>
                    <measurement group_id="O9" value="-1.586" spread="1.0710"/>
                    <measurement group_id="O10" value="-1.742" spread="1.3842"/>
                    <measurement group_id="O11" value="-1.380" spread="1.6686"/>
                    <measurement group_id="O12" value="-1.892" spread="1.0143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.2740"/>
                    <measurement group_id="O2" value="-0.941" spread="0.5345"/>
                    <measurement group_id="O3" value="-2.074" spread="0.7701"/>
                    <measurement group_id="O4" value="-1.702" spread="1.6152"/>
                    <measurement group_id="O5" value="-1.780" spread="0.9987"/>
                    <measurement group_id="O6" value="-2.544" spread="1.5460"/>
                    <measurement group_id="O7" value="-4.026" spread="0.3155"/>
                    <measurement group_id="O8" value="-3.559" spread="0.9866"/>
                    <measurement group_id="O9" value="-1.025" spread="1.1864"/>
                    <measurement group_id="O10" value="-1.542" spread="1.0593"/>
                    <measurement group_id="O11" value="-1.062" spread="1.5998"/>
                    <measurement group_id="O12" value="-1.478" spread="1.1542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.142" spread="0.3813"/>
                    <measurement group_id="O2" value="-0.679" spread="0.4352"/>
                    <measurement group_id="O3" value="-1.304" spread="1.0374"/>
                    <measurement group_id="O4" value="-1.472" spread="1.4315"/>
                    <measurement group_id="O5" value="-1.143" spread="1.2137"/>
                    <measurement group_id="O6" value="-2.032" spread="1.4388"/>
                    <measurement group_id="O7" value="-3.348" spread="0.6201"/>
                    <measurement group_id="O8" value="-2.918" spread="1.1566"/>
                    <measurement group_id="O9" value="-0.844" spread="0.6967"/>
                    <measurement group_id="O10" value="-1.051" spread="1.4338"/>
                    <measurement group_id="O11" value="-1.198" spread="1.0991"/>
                    <measurement group_id="O12" value="-0.494" spread="0.8933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" spread="0.2719"/>
                    <measurement group_id="O2" value="-0.135" spread="0.3747"/>
                    <measurement group_id="O3" value="-0.223" spread="0.4236"/>
                    <measurement group_id="O4" value="-1.110" spread="1.3584"/>
                    <measurement group_id="O5" value="-0.801" spread="0.7679"/>
                    <measurement group_id="O6" value="-0.879" spread="0.9231"/>
                    <measurement group_id="O7" value="-1.532" spread="1.2059"/>
                    <measurement group_id="O8" value="-0.886" spread="1.3190"/>
                    <measurement group_id="O9" value="-0.672" spread="0.5003"/>
                    <measurement group_id="O10" value="-0.085" spread="0.6910"/>
                    <measurement group_id="O11" value="-0.225" spread="0.4210"/>
                    <measurement group_id="O12" value="-0.351" spread="0.5914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute HCV RNA Level</title>
        <time_frame>Baseline; Days 4, 5, 6, 7, 8, 10, and 17</time_frame>
        <population>Participants in the Efficacy Analysis Set with available data were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 5 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 25 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 50 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 100 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Velpatasvir 150 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Velpatasvir 150 mg (GT 1b)</title>
            <description>Participants with GT 1b HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Velpatasvir 150 mg (GT 2)</title>
            <description>Participants with GT 2 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Velpatasvir 25 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Velpatasvir 50 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Velpatasvir 150 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Velpatasvir 150 mg (GT 4)</title>
            <description>Participants with GT 4 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute HCV RNA Level</title>
          <population>Participants in the Efficacy Analysis Set with available data were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.523" spread="0.5173"/>
                    <measurement group_id="O2" value="6.639" spread="0.3123"/>
                    <measurement group_id="O3" value="6.461" spread="0.6623"/>
                    <measurement group_id="O4" value="6.459" spread="0.5726"/>
                    <measurement group_id="O5" value="6.458" spread="0.4785"/>
                    <measurement group_id="O6" value="6.335" spread="0.5710"/>
                    <measurement group_id="O7" value="6.379" spread="0.4187"/>
                    <measurement group_id="O8" value="6.753" spread="0.5857"/>
                    <measurement group_id="O9" value="6.150" spread="1.0108"/>
                    <measurement group_id="O10" value="6.240" spread="0.5796"/>
                    <measurement group_id="O11" value="6.318" spread="0.8151"/>
                    <measurement group_id="O12" value="5.734" spread="0.2345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.518" spread="0.4840"/>
                    <measurement group_id="O2" value="3.535" spread="0.7588"/>
                    <measurement group_id="O3" value="2.823" spread="0.7866"/>
                    <measurement group_id="O4" value="3.121" spread="1.6969"/>
                    <measurement group_id="O5" value="3.304" spread="1.2823"/>
                    <measurement group_id="O6" value="2.687" spread="0.8776"/>
                    <measurement group_id="O7" value="2.574" spread="0.3526"/>
                    <measurement group_id="O8" value="2.708" spread="0.5823"/>
                    <measurement group_id="O9" value="3.151" spread="2.0090"/>
                    <measurement group_id="O10" value="3.858" spread="1.9120"/>
                    <measurement group_id="O11" value="3.484" spread="0.6784"/>
                    <measurement group_id="O12" value="2.465" spread="0.8425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.512" spread="0.5715"/>
                    <measurement group_id="O2" value="4.642" spread="0.9016"/>
                    <measurement group_id="O3" value="2.922" spread="1.0852"/>
                    <measurement group_id="O4" value="3.336" spread="1.8716"/>
                    <measurement group_id="O5" value="3.398" spread="1.3325"/>
                    <measurement group_id="O6" value="2.699" spread="1.0083"/>
                    <measurement group_id="O7" value="2.466" spread="0.3511"/>
                    <measurement group_id="O8" value="2.681" spread="0.3893"/>
                    <measurement group_id="O9" value="3.329" spread="1.8305"/>
                    <measurement group_id="O10" value="4.110" spread="1.8964"/>
                    <measurement group_id="O11" value="4.059" spread="1.0186"/>
                    <measurement group_id="O12" value="2.907" spread="0.7850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.493" spread="0.5373"/>
                    <measurement group_id="O2" value="5.395" spread="0.6898"/>
                    <measurement group_id="O3" value="3.321" spread="1.3322"/>
                    <measurement group_id="O4" value="3.755" spread="1.9323"/>
                    <measurement group_id="O5" value="3.745" spread="1.3213"/>
                    <measurement group_id="O6" value="3.104" spread="1.2373"/>
                    <measurement group_id="O7" value="2.400" spread="0.3365"/>
                    <measurement group_id="O8" value="2.644" spread="0.6568"/>
                    <measurement group_id="O9" value="3.753" spread="1.6214"/>
                    <measurement group_id="O10" value="4.503" spread="1.9383"/>
                    <measurement group_id="O11" value="4.450" spread="1.1943"/>
                    <measurement group_id="O12" value="3.491" spread="0.8264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.527" spread="0.6190"/>
                    <measurement group_id="O2" value="5.608" spread="0.6929"/>
                    <measurement group_id="O3" value="4.036" spread="1.1305"/>
                    <measurement group_id="O4" value="4.275" spread="1.9196"/>
                    <measurement group_id="O5" value="4.185" spread="1.4107"/>
                    <measurement group_id="O6" value="3.862" spread="1.4141"/>
                    <measurement group_id="O7" value="2.217" spread="0.5807"/>
                    <measurement group_id="O8" value="2.903" spread="0.7639"/>
                    <measurement group_id="O9" value="4.361" spread="1.4130"/>
                    <measurement group_id="O10" value="4.498" spread="1.9226"/>
                    <measurement group_id="O11" value="4.938" spread="1.4707"/>
                    <measurement group_id="O12" value="3.842" spread="1.2488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.555" spread="0.4880"/>
                    <measurement group_id="O2" value="5.699" spread="0.6305"/>
                    <measurement group_id="O3" value="4.387" spread="1.1089"/>
                    <measurement group_id="O4" value="4.756" spread="1.9494"/>
                    <measurement group_id="O5" value="4.678" spread="1.3233"/>
                    <measurement group_id="O6" value="3.791" spread="1.5984"/>
                    <measurement group_id="O7" value="2.396" spread="0.6092"/>
                    <measurement group_id="O8" value="3.194" spread="0.8402"/>
                    <measurement group_id="O9" value="4.922" spread="1.3395"/>
                    <measurement group_id="O10" value="4.698" spread="1.6047"/>
                    <measurement group_id="O11" value="5.256" spread="1.3141"/>
                    <measurement group_id="O12" value="4.256" spread="1.3887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.659" spread="0.4583"/>
                    <measurement group_id="O2" value="5.960" spread="0.6104"/>
                    <measurement group_id="O3" value="5.156" spread="1.3456"/>
                    <measurement group_id="O4" value="4.986" spread="1.7558"/>
                    <measurement group_id="O5" value="5.315" spread="1.5130"/>
                    <measurement group_id="O6" value="4.319" spread="1.6357"/>
                    <measurement group_id="O7" value="3.074" spread="0.8660"/>
                    <measurement group_id="O8" value="3.834" spread="1.1710"/>
                    <measurement group_id="O9" value="5.103" spread="1.1273"/>
                    <measurement group_id="O10" value="5.190" spread="2.0061"/>
                    <measurement group_id="O11" value="5.120" spread="0.6140"/>
                    <measurement group_id="O12" value="5.240" spread="1.1278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.503" spread="0.5432"/>
                    <measurement group_id="O2" value="6.505" spread="0.5615"/>
                    <measurement group_id="O3" value="6.237" spread="0.6709"/>
                    <measurement group_id="O4" value="5.468" spread="1.6269"/>
                    <measurement group_id="O5" value="5.657" spread="1.0148"/>
                    <measurement group_id="O6" value="5.455" spread="1.2889"/>
                    <measurement group_id="O7" value="4.890" spread="1.5438"/>
                    <measurement group_id="O8" value="5.867" spread="1.5443"/>
                    <measurement group_id="O9" value="5.275" spread="1.1421"/>
                    <measurement group_id="O10" value="6.007" spread="0.9524"/>
                    <measurement group_id="O11" value="6.093" spread="0.6451"/>
                    <measurement group_id="O12" value="5.383" spread="0.8259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Reductions From Baseline in HCV RNA</title>
        <description>Categorical declines from baseline were summarized by the number of participants with a &lt; 1, ≥ 1 to &lt; 2, ≥ 2 to &lt; 3, or ≥ 3 log10 IU/mL decrease in HCV RNA from baseline by treatment (velpatasvir dose/HCV genotype) and placebo at each collection time point through Day 17.</description>
        <time_frame>Baseline; Days 4, 5, 6, 7, 8, 10, and 17</time_frame>
        <population>Participants in the Efficacy Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 5 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 25 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 50 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 100 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Velpatasvir 150 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Velpatasvir 150 mg (GT 1b)</title>
            <description>Participants with GT 1b HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Velpatasvir 150 mg (GT 2)</title>
            <description>Participants with GT 2 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Velpatasvir 25 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Velpatasvir 50 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Velpatasvir 150 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Velpatasvir 150 mg (GT 4)</title>
            <description>Participants with GT 4 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Reductions From Baseline in HCV RNA</title>
          <description>Categorical declines from baseline were summarized by the number of participants with a &lt; 1, ≥ 1 to &lt; 2, ≥ 2 to &lt; 3, or ≥ 3 log10 IU/mL decrease in HCV RNA from baseline by treatment (velpatasvir dose/HCV genotype) and placebo at each collection time point through Day 17.</description>
          <population>Participants in the Efficacy Analysis Set were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <title>Missing HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 1 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1 and &lt;2 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 and &lt;3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <title>Missing HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 1 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1 and &lt;2 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 and &lt;3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <title>Missing HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 1 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1 and &lt;2 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 and &lt;3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <title>Missing HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 1 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1 and &lt;2 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 and &lt;3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <title>Missing HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 1 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1 and &lt;2 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 and &lt;3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <title>Missing HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 1 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1 and &lt;2 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 and &lt;3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <title>Missing HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 1 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1 and &lt;2 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 and &lt;3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3 log10 IU/mL decrease in HCV RNA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have HCV RNA &lt; Lower Limit of Quantitation (LLOQ) Detected</title>
        <description>The lower limit of quantitation (LLOQ) detection for HCV RNA levels was 25 IU/mL. HCV detected means calculated HCV RNA level is below LLOQ of the assay.</description>
        <time_frame>Days 4, 5, 6, 7, and 8</time_frame>
        <population>Participants in the Efficacy Analysis Set were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 5 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 25 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 50 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 100 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Velpatasvir 150 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Velpatasvir 150 mg (GT 1b)</title>
            <description>Participants with GT 1b HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Velpatasvir 150 mg (GT 2)</title>
            <description>Participants with GT 2 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Velpatasvir 25 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Velpatasvir 50 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Velpatasvir 150 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Velpatasvir 150 mg (GT 4)</title>
            <description>Participants with GT 4 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have HCV RNA &lt; Lower Limit of Quantitation (LLOQ) Detected</title>
          <description>The lower limit of quantitation (LLOQ) detection for HCV RNA levels was 25 IU/mL. HCV detected means calculated HCV RNA level is below LLOQ of the assay.</description>
          <population>Participants in the Efficacy Analysis Set were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4 &lt; LLOQ detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 &lt; LLOQ detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 &lt; LLOQ detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 &lt; LLOQ detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 &lt; LLOQ detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma HCV RNA Levels by Treatment and IL28B Genotype</title>
        <time_frame>Days 4, 5, 6, 7, 8, 10, and 17</time_frame>
        <population>Participants in the Efficacy Analysis Set with available data were analyzed. Data are were summarized by treatment (velpatasvir dose/HCV genotype and placebo) and IL28B genotype (CC and non-CC). Due to the small number of participants in each treatment group, no conclusions can be made on the effect of IL28B genotype on HCV RNA decline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (IL28B Genotype CC)</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 5 mg (GT 1a) (IL28B Genotype CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 25 mg (GT 1a) (IL28B Genotype CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 50 mg (GT 1a) (IL28B Genotype CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 100 mg (GT 1a) (IL28B Genotype CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Velpatasvir 150 mg (GT 1a) (IL28B Genotype CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Velpatasvir 150 mg (GT 1b) (IL28B Genotype CC)</title>
            <description>Participants with GT 1b HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Velpatasvir 150 mg (GT 2) (IL28B Genotype CC)</title>
            <description>Participants with GT 2 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Velpatasvir 25 mg (GT 3) (IL28B Genotype CC)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Velpatasvir 50 mg (GT 3) (IL28B Genotype CC)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Velpatasvir 150 mg (GT 3) (IL28B Genotype CC)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Velpatasvir 150 mg (GT 4) (IL28B Genotype CC)</title>
            <description>Participants with GT 4 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O13">
            <title>Placebo (IL28B Genotype Non-CC)</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O14">
            <title>Velpatasvir 5 mg (GT 1a) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O15">
            <title>Velpatasvir 25 mg (GT 1a) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O16">
            <title>Velpatasvir 50 mg (GT 1a) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O17">
            <title>Velpatasvir 100 mg (GT 1a) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O18">
            <title>Velpatasvir 150 mg (GT 1a) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O19">
            <title>Velpatasvir 150 mg (GT 1b) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 1b HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O20">
            <title>Velpatasvir 150 mg (GT 2) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 2 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O21">
            <title>Velpatasvir 25 mg (GT 3) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O22">
            <title>Velpatasvir 50 mg (GT 3) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O23">
            <title>Velpatasvir 150 mg (GT 3) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O24">
            <title>Velpatasvir 150 mg (GT 4) (IL28B Genotype Non-CC)</title>
            <description>Participants with GT 4 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma HCV RNA Levels by Treatment and IL28B Genotype</title>
          <population>Participants in the Efficacy Analysis Set with available data were analyzed. Data are were summarized by treatment (velpatasvir dose/HCV genotype and placebo) and IL28B genotype (CC and non-CC). Due to the small number of participants in each treatment group, no conclusions can be made on the effect of IL28B genotype on HCV RNA decline.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="5"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="6"/>
                <count group_id="O18" value="7"/>
                <count group_id="O19" value="7"/>
                <count group_id="O20" value="5"/>
                <count group_id="O21" value="5"/>
                <count group_id="O22" value="1"/>
                <count group_id="O23" value="5"/>
                <count group_id="O24" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="2"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="6"/>
                    <count group_id="O17" value="6"/>
                    <count group_id="O18" value="7"/>
                    <count group_id="O19" value="6"/>
                    <count group_id="O20" value="5"/>
                    <count group_id="O21" value="5"/>
                    <count group_id="O22" value="1"/>
                    <count group_id="O23" value="5"/>
                    <count group_id="O24" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.473" spread="0.4869"/>
                    <measurement group_id="O2" value="3.410" spread="0.4007"/>
                    <measurement group_id="O3" value="2.603" spread="0.5255"/>
                    <measurement group_id="O4" value="1.762" spread="0.5394"/>
                    <measurement group_id="O5" value="2.891" spread="0.4237"/>
                    <measurement group_id="O7" value="2.539"/>
                    <measurement group_id="O8" value="2.758" spread="0.3416"/>
                    <measurement group_id="O9" value="2.976"/>
                    <measurement group_id="O10" value="4.304" spread="2.0716"/>
                    <measurement group_id="O11" value="3.590"/>
                    <measurement group_id="O13" value="6.549" spread="0.5057"/>
                    <measurement group_id="O14" value="3.660" spread="1.2265"/>
                    <measurement group_id="O15" value="2.955" spread="0.9418"/>
                    <measurement group_id="O16" value="3.574" spread="1.7284"/>
                    <measurement group_id="O17" value="3.442" spread="1.4747"/>
                    <measurement group_id="O18" value="2.687" spread="0.8776"/>
                    <measurement group_id="O19" value="2.579" spread="0.3859"/>
                    <measurement group_id="O20" value="2.678" spread="0.7295"/>
                    <measurement group_id="O21" value="3.186" spread="2.2441"/>
                    <measurement group_id="O22" value="2.521"/>
                    <measurement group_id="O23" value="3.463" spread="0.7562"/>
                    <measurement group_id="O24" value="2.465" spread="0.8425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="9"/>
                    <count group_id="O14" value="2"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="6"/>
                    <count group_id="O17" value="6"/>
                    <count group_id="O18" value="7"/>
                    <count group_id="O19" value="6"/>
                    <count group_id="O20" value="3"/>
                    <count group_id="O21" value="5"/>
                    <count group_id="O22" value="1"/>
                    <count group_id="O23" value="5"/>
                    <count group_id="O24" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.604" spread="0.4842"/>
                    <measurement group_id="O2" value="4.578" spread="0.6202"/>
                    <measurement group_id="O3" value="2.581" spread="1.0972"/>
                    <measurement group_id="O4" value="1.748" spread="0.0110"/>
                    <measurement group_id="O5" value="2.996" spread="0.4644"/>
                    <measurement group_id="O7" value="2.605"/>
                    <measurement group_id="O8" value="2.689" spread="0.5473"/>
                    <measurement group_id="O9" value="3.117"/>
                    <measurement group_id="O10" value="4.620" spread="1.9568"/>
                    <measurement group_id="O11" value="3.742"/>
                    <measurement group_id="O13" value="6.450" spread="0.6437"/>
                    <measurement group_id="O14" value="4.705" spread="1.4275"/>
                    <measurement group_id="O15" value="3.127" spread="1.1484"/>
                    <measurement group_id="O16" value="3.865" spread="1.8868"/>
                    <measurement group_id="O17" value="3.532" spread="1.5350"/>
                    <measurement group_id="O18" value="2.699" spread="1.0083"/>
                    <measurement group_id="O19" value="2.443" spread="0.3787"/>
                    <measurement group_id="O20" value="2.673" spread="0.2813"/>
                    <measurement group_id="O21" value="3.372" spread="2.0433"/>
                    <measurement group_id="O22" value="2.577"/>
                    <measurement group_id="O23" value="4.123" spread="1.1255"/>
                    <measurement group_id="O24" value="2.907" spread="0.7850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="9"/>
                    <count group_id="O14" value="2"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="6"/>
                    <count group_id="O17" value="6"/>
                    <count group_id="O18" value="6"/>
                    <count group_id="O19" value="6"/>
                    <count group_id="O20" value="5"/>
                    <count group_id="O21" value="5"/>
                    <count group_id="O22" value="1"/>
                    <count group_id="O23" value="5"/>
                    <count group_id="O24" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.595" spread="0.3266"/>
                    <measurement group_id="O2" value="5.388" spread="0.5909"/>
                    <measurement group_id="O3" value="2.740" spread="1.2380"/>
                    <measurement group_id="O4" value="2.134" spread="0.3192"/>
                    <measurement group_id="O5" value="3.138" spread="0.5754"/>
                    <measurement group_id="O7" value="2.801"/>
                    <measurement group_id="O8" value="2.668" spread="0.7974"/>
                    <measurement group_id="O9" value="3.813"/>
                    <measurement group_id="O10" value="5.035" spread="1.9842"/>
                    <measurement group_id="O11" value="3.653"/>
                    <measurement group_id="O13" value="6.426" spread="0.6525"/>
                    <measurement group_id="O14" value="5.403" spread="1.0383"/>
                    <measurement group_id="O15" value="3.669" spread="1.3910"/>
                    <measurement group_id="O16" value="4.295" spread="1.9510"/>
                    <measurement group_id="O17" value="3.947" spread="1.4771"/>
                    <measurement group_id="O18" value="3.104" spread="1.2373"/>
                    <measurement group_id="O19" value="2.334" spread="0.3139"/>
                    <measurement group_id="O20" value="2.629" spread="0.6604"/>
                    <measurement group_id="O21" value="3.741" spread="1.8125"/>
                    <measurement group_id="O22" value="2.907"/>
                    <measurement group_id="O23" value="4.609" spread="1.2620"/>
                    <measurement group_id="O24" value="3.491" spread="0.8264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="9"/>
                    <count group_id="O14" value="2"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="6"/>
                    <count group_id="O17" value="6"/>
                    <count group_id="O18" value="5"/>
                    <count group_id="O19" value="6"/>
                    <count group_id="O20" value="5"/>
                    <count group_id="O21" value="5"/>
                    <count group_id="O22" value="1"/>
                    <count group_id="O23" value="5"/>
                    <count group_id="O24" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.563" spread="0.3311"/>
                    <measurement group_id="O2" value="5.612" spread="0.4912"/>
                    <measurement group_id="O3" value="3.637" spread="0.7489"/>
                    <measurement group_id="O4" value="2.988" spread="0.7310"/>
                    <measurement group_id="O5" value="3.390" spread="0.1908"/>
                    <measurement group_id="O7" value="3.312"/>
                    <measurement group_id="O8" value="2.684" spread="1.0300"/>
                    <measurement group_id="O9" value="4.196"/>
                    <measurement group_id="O10" value="5.038" spread="1.9476"/>
                    <measurement group_id="O11" value="3.713"/>
                    <measurement group_id="O13" value="6.504" spread="0.7748"/>
                    <measurement group_id="O14" value="5.604" spread="1.0949"/>
                    <measurement group_id="O15" value="4.276" spread="1.3284"/>
                    <measurement group_id="O16" value="4.704" spread="2.0419"/>
                    <measurement group_id="O17" value="4.449" spread="1.5628"/>
                    <measurement group_id="O18" value="3.862" spread="1.4141"/>
                    <measurement group_id="O19" value="2.034" spread="0.3534"/>
                    <measurement group_id="O20" value="3.034" spread="0.6583"/>
                    <measurement group_id="O21" value="4.394" spread="1.5772"/>
                    <measurement group_id="O22" value="2.877"/>
                    <measurement group_id="O23" value="5.183" spread="1.5012"/>
                    <measurement group_id="O24" value="3.842" spread="1.2488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="2"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="6"/>
                    <count group_id="O17" value="6"/>
                    <count group_id="O18" value="7"/>
                    <count group_id="O19" value="6"/>
                    <count group_id="O20" value="5"/>
                    <count group_id="O21" value="5"/>
                    <count group_id="O22" value="1"/>
                    <count group_id="O23" value="5"/>
                    <count group_id="O24" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.643" spread="0.4611"/>
                    <measurement group_id="O2" value="5.744" spread="0.7194"/>
                    <measurement group_id="O3" value="3.875" spread="0.5026"/>
                    <measurement group_id="O4" value="3.053" spread="1.1852"/>
                    <measurement group_id="O5" value="3.867" spread="0.3347"/>
                    <measurement group_id="O7" value="3.441"/>
                    <measurement group_id="O8" value="2.913" spread="1.0913"/>
                    <measurement group_id="O9" value="4.553"/>
                    <measurement group_id="O10" value="5.123" spread="1.6669"/>
                    <measurement group_id="O11" value="4.114"/>
                    <measurement group_id="O13" value="6.503" spread="0.5202"/>
                    <measurement group_id="O14" value="5.653" spread="0.8166"/>
                    <measurement group_id="O15" value="4.694" spread="1.3082"/>
                    <measurement group_id="O16" value="5.324" spread="1.8687"/>
                    <measurement group_id="O17" value="4.949" spread="1.4416"/>
                    <measurement group_id="O18" value="3.791" spread="1.5984"/>
                    <measurement group_id="O19" value="2.222" spread="0.4366"/>
                    <measurement group_id="O20" value="3.362" spread="0.7384"/>
                    <measurement group_id="O21" value="4.996" spread="1.4838"/>
                    <measurement group_id="O22" value="3.423"/>
                    <measurement group_id="O23" value="5.485" spread="1.3293"/>
                    <measurement group_id="O24" value="4.256" spread="1.3887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="2"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="6"/>
                    <count group_id="O17" value="6"/>
                    <count group_id="O18" value="6"/>
                    <count group_id="O19" value="6"/>
                    <count group_id="O20" value="5"/>
                    <count group_id="O21" value="5"/>
                    <count group_id="O22" value="1"/>
                    <count group_id="O23" value="5"/>
                    <count group_id="O24" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.817" spread="0.3336"/>
                    <measurement group_id="O2" value="6.171" spread="0.8102"/>
                    <measurement group_id="O3" value="4.369" spread="0.3684"/>
                    <measurement group_id="O4" value="3.488" spread="1.1964"/>
                    <measurement group_id="O5" value="4.059" spread="0.0027"/>
                    <measurement group_id="O7" value="3.948"/>
                    <measurement group_id="O8" value="3.438" spread="1.2872"/>
                    <measurement group_id="O9" value="5.061"/>
                    <measurement group_id="O10" value="5.724" spread="2.0787"/>
                    <measurement group_id="O11" value="4.754"/>
                    <measurement group_id="O13" value="6.580" spread="0.5065"/>
                    <measurement group_id="O14" value="5.750" spread="0.5333"/>
                    <measurement group_id="O15" value="5.629" spread="1.5354"/>
                    <measurement group_id="O16" value="5.485" spread="1.6832"/>
                    <measurement group_id="O17" value="5.733" spread="1.5375"/>
                    <measurement group_id="O18" value="4.319" spread="1.6357"/>
                    <measurement group_id="O19" value="2.928" spread="0.8495"/>
                    <measurement group_id="O20" value="4.073" spread="1.1757"/>
                    <measurement group_id="O21" value="5.111" spread="1.2601"/>
                    <measurement group_id="O22" value="3.585"/>
                    <measurement group_id="O23" value="5.193" spread="0.6566"/>
                    <measurement group_id="O24" value="5.240" spread="1.1278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="2"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="6"/>
                    <count group_id="O17" value="6"/>
                    <count group_id="O18" value="7"/>
                    <count group_id="O19" value="6"/>
                    <count group_id="O20" value="5"/>
                    <count group_id="O21" value="5"/>
                    <count group_id="O22" value="1"/>
                    <count group_id="O23" value="5"/>
                    <count group_id="O24" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.601" spread="0.3466"/>
                    <measurement group_id="O2" value="6.713" spread="0.6714"/>
                    <measurement group_id="O3" value="6.147" spread="1.0166"/>
                    <measurement group_id="O4" value="2.949"/>
                    <measurement group_id="O5" value="4.572" spread="0.1838"/>
                    <measurement group_id="O7" value="6.953"/>
                    <measurement group_id="O8" value="5.127" spread="1.8225"/>
                    <measurement group_id="O9" value="6.744"/>
                    <measurement group_id="O10" value="5.881" spread="1.3108"/>
                    <measurement group_id="O11" value="6.621"/>
                    <measurement group_id="O13" value="6.444" spread="0.6440"/>
                    <measurement group_id="O14" value="6.297" spread="0.5676"/>
                    <measurement group_id="O15" value="6.292" spread="0.5110"/>
                    <measurement group_id="O16" value="5.888" spread="1.3019"/>
                    <measurement group_id="O17" value="6.019" spread="0.8985"/>
                    <measurement group_id="O18" value="5.455" spread="1.2889"/>
                    <measurement group_id="O19" value="4.546" spread="1.3663"/>
                    <measurement group_id="O20" value="6.311" spread="1.3623"/>
                    <measurement group_id="O21" value="4.981" spread="0.9912"/>
                    <measurement group_id="O22" value="6.260"/>
                    <measurement group_id="O23" value="5.987" spread="0.6606"/>
                    <measurement group_id="O24" value="5.383" spread="0.8259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf</title>
        <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
        <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1</time_frame>
        <population>The PK analysis set included all randomized and treated participants who have evaluable PK profiles for velpatasvir.</population>
        <group_list>
          <group group_id="O1">
            <title>Velpatasvir 5 mg</title>
            <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 25 mg</title>
            <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 50 mg</title>
            <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 100 mg</title>
            <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 150 mg</title>
            <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf</title>
          <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
          <population>The PK analysis set included all randomized and treated participants who have evaluable PK profiles for velpatasvir.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.8" spread="71.61"/>
                    <measurement group_id="O2" value="857.9" spread="612.23"/>
                    <measurement group_id="O3" value="2054.3" spread="806.69"/>
                    <measurement group_id="O4" value="2727.3" spread="1619.74"/>
                    <measurement group_id="O5" value="4546.6" spread="1757.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter of Velpatasvir: AUCtau</title>
        <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
        <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 3</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Velpatasvir 5 mg</title>
            <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 25 mg</title>
            <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 50 mg</title>
            <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 100 mg</title>
            <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 150 mg</title>
            <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter of Velpatasvir: AUCtau</title>
          <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" spread="14.32"/>
                    <measurement group_id="O2" value="857.5" spread="467.74"/>
                    <measurement group_id="O3" value="1950.5" spread="486.87"/>
                    <measurement group_id="O4" value="2745.3" spread="1480.47"/>
                    <measurement group_id="O5" value="5003.0" spread="2371.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter of Velpatasvir: Cmax</title>
        <description>Cmax is defined as the maximum observed plasma concentration of drug.</description>
        <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1 for single dose and Day 3 for multiple dose.</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Velpatasvir 5 mg</title>
            <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 25 mg</title>
            <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 50 mg</title>
            <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 100 mg</title>
            <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 150 mg</title>
            <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter of Velpatasvir: Cmax</title>
          <description>Cmax is defined as the maximum observed plasma concentration of drug.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Single-Dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="14.62"/>
                    <measurement group_id="O2" value="110.8" spread="55.97"/>
                    <measurement group_id="O3" value="272.3" spread="95.46"/>
                    <measurement group_id="O4" value="372.8" spread="222.74"/>
                    <measurement group_id="O5" value="583.3" spread="257.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (Multiple-Dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="2.34"/>
                    <measurement group_id="O2" value="122.9" spread="61.38"/>
                    <measurement group_id="O3" value="292.4" spread="88.77"/>
                    <measurement group_id="O4" value="413.9" spread="243.66"/>
                    <measurement group_id="O5" value="690.1" spread="307.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter of Velpatasvir: CL/F</title>
        <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
        <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1 for single dose and Day 3 for multiple dose</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Velpatasvir 5 mg</title>
            <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 25 mg</title>
            <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 50 mg</title>
            <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 100 mg</title>
            <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 150 mg</title>
            <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter of Velpatasvir: CL/F</title>
          <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61312.2" spread="42726.76"/>
                    <measurement group_id="O2" value="37170.7" spread="16570.51"/>
                    <measurement group_id="O3" value="27930.6" spread="10689.18"/>
                    <measurement group_id="O4" value="49237.5" spread="25550.98"/>
                    <measurement group_id="O5" value="38011.7" spread="14392.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59173.6" spread="10490.08"/>
                    <measurement group_id="O2" value="34,820.1" spread="13217.45"/>
                    <measurement group_id="O3" value="27,263.0" spread="7367.47"/>
                    <measurement group_id="O4" value="53,194.3" spread="39618.97"/>
                    <measurement group_id="O5" value="37,362.8" spread="18382.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter of Velpatasvir: Ctau</title>
        <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
        <time_frame>0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 3</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Velpatasvir 5 mg</title>
            <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 25 mg</title>
            <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 50 mg</title>
            <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 100 mg</title>
            <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 150 mg</title>
            <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter of Velpatasvir: Ctau</title>
          <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.70"/>
                    <measurement group_id="O2" value="10.8" spread="8.50"/>
                    <measurement group_id="O3" value="22.4" spread="4.66"/>
                    <measurement group_id="O4" value="30.8" spread="15.03"/>
                    <measurement group_id="O5" value="60.6" spread="33.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints</title>
        <description>The full-length NS5A coding region was analyzed pretreatment (baseline) by deep sequencing using MiSeq for all 70 participants who received velpatasvir and for 8 of 17 participants who received placebo prior to and up to 2 weeks (Day 17) after dosing with velpatasvir. Participants were categorized by velpatasvir dose/HCV genotype and presence or absence of NS5A RAVs.</description>
        <time_frame>First dose date up to Day 17</time_frame>
        <population>Participants in the efficacy analysis set who were sequenced at pre-treatment or post baseline treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Velpatasvir 5 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Velpatasvir 25 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Velpatasvir 50 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Velpatasvir 100 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Velpatasvir 150 mg (GT 1a)</title>
            <description>Participants with GT 1a HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Velpatasvir 150 mg (GT 1b)</title>
            <description>Participants with GT 1b HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Velpatasvir 150 mg (GT 2)</title>
            <description>Participants with GT 2 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Velpatasvir 25 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Velpatasvir 50 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Velpatasvir 150 mg (GT 3)</title>
            <description>Participants with GT 3 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Velpatasvir 150 mg (GT 4)</title>
            <description>Participants with GT 4 HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints</title>
          <description>The full-length NS5A coding region was analyzed pretreatment (baseline) by deep sequencing using MiSeq for all 70 participants who received velpatasvir and for 8 of 17 participants who received placebo prior to and up to 2 weeks (Day 17) after dosing with velpatasvir. Participants were categorized by velpatasvir dose/HCV genotype and presence or absence of NS5A RAVs.</description>
          <population>Participants in the efficacy analysis set who were sequenced at pre-treatment or post baseline treatment were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants sequenced pretreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with RAVs at pretreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants sequenced at postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with RAVs at postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events: First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing); All-Cause Mortality: First dose date up to Week 48</time_frame>
      <desc>The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug (velpatasvir or placebo). Data were summarized by velpatasvir and placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants with HCV infection received placebo once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="E2">
          <title>Velpatasvir 5 mg</title>
          <description>Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="E3">
          <title>Velpatasvir 25 mg</title>
          <description>Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="E4">
          <title>Velpatasvir 50 mg</title>
          <description>Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="E5">
          <title>Velpatasvir 100 mg</title>
          <description>Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.</description>
        </group>
        <group group_id="E6">
          <title>Velpatasvir 150 mg</title>
          <description>Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

